CHICAGO, Jan. 27, 2017 -- A recent study found that Varium™, the natural growth promoter for poultry from Amlan International, performed better than antibiotics alone, delivering significant reductions in mortality, and improvements in feed conversion and intestinal health, for a 10:1 return on investment.
“As the reduction or elimination of antibiotics in broiler production continues to expand worldwide, Varium is proving to be an effective way to enhance the growth-promoting abilities of antibiotics, or, when used in antibiotic-free production, to achieve bird performance equivalent to flocks receiving sub-therapeutic levels of antibiotics,” said Dr. Ron Cravens, President of Amlan International, a Nevada Corporation.
“We’re very pleased our customers’ broilers receiving Varium experienced improved villi height and a reduction in crypt depth indicating improved intestinal integrity,” said Cravens. “It’s quite notable that an improved European Efficiency Index (EEI) score was also seen, increasing from 350 to 400 points.”
Compared to the control diet that included antibiotics, feeding Varium decreased mortality by 40%, from 6.93% to 4.18%, with improvements seen throughout the growout period, not just in young birds. Feed conversion improved 15 points, from 1.64 to 1.49, with the majority of the gains seen after day 7 and a greater response seen in female broilers.
Varium is a registered product in a variety of countries, including China and Mexico. For a full list of registered countries and a complete study of the results and more information on Varium, please visit Amlan.com. Varium is sold outside the U.S.
About Amlan International
Oil-Dri Corporation of America (NYSE:ODC), doing business as Amlan International, helps producers increase animal productivity by developing products that enhance intestinal health and function. Since its inception in 2007, Amlan has grown its product offering across the intestinal health and AGP-alternative market, driven largely by the research conducted in its laboratory campus in Vernon Hills, IL. In 2013, the company’s global reach expanded with the establishment of its China subsidiary in Shenzhen. Further information on Amlan International is available at Amlan.com. Amlan–Productivity for Life.
Media Contact Mike McPherson 312.706.3379 [email protected] www.amlan.com


Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Instagram Outage Disrupts Thousands of U.S. Users
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 



